LP

LB Pharmaceuticals Inc Common Stock

LBRX·NASDAQ

$27.95

+3.4%
HealthcareBiotechnology

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

At a Glance

Live Snapshot
Market Cap$801.51M
EPS-1.0000
P/E Ratio-27.95
Earnings Date06/25/2026

lbrx

Short Term Debt

Last Annual Value

730.00K

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

LP

LB Pharmaceuticals Inc Common Stock Competitors Analysis of Short Term Debt

LBRX · NASDAQ
CompanyShort Term Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
730.00K
N/AN/AN/A 
3.24M
N/AN/AN/A
ANNX logo
Annexon, Inc.
NASDAQ:ANNX
0.00
N/AN/AN/A
11.03M
-2.8%N/A1.0%
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
2.43M
N/AN/AN/A
3.97M
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
3.02M
N/A8.7%N/A
2.92M
N/AN/AN/A
KRRO logo
Korro Bio, Inc.
NASDAQ:KRRO
2.67M
N/A0.7%N/A
LP

LB Pharmaceuticals Inc Common Stock Fair Value Envelope

LBRX · NASDAQ

Our analysis suggests that LBRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.95, this represents a potential HIDDEN relative to our calculated worth for LB Pharmaceuticals Inc Common Stock.

Intrinsic Value
Current Price: $27.95